Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Nvidia's CFO Just Explained Why the AI Boom Is Eating Its Gross Margin -- and It's a Green Light for Micron

Key PointsNvidia's second-quarter earnings results were incredible, with data center sales growing 117% year over year.

Nvidia's fiscal 2027 second-quarter earnings report revealed that the company is at the epicenter of the artificial intelligence (AI) infrastructure build-out. Total revenue skyrocketed to $96.2 billion, more than doubling the $46.7 billion generated a year prior and up 18% from the prior quarter. However, the most striking figure lies within the underlying sales mix, with Nvidia's data center segment alone accounting for $89 billion in revenue.

This single segment now generates more sales than Nvidia's entire company did just one year ago, underscoring the hyperscaler capital expenditure (capex) boom is no longer a mere abstract concept. Cloud providers and AI infrastructure developers are ramping up capacity at a full pace, and Nvidia is converting this spend with extraordinary efficiency.

Despite these impressive figures, Nvidia's earnings report also contained a subtle message that may prove even more significant for the next player in the AI chip value chain: Micron Technology (NASDAQ: MU). Management provided guidance for a lower gross margin, and the explanation pointed directly at memory. This indicates that Nvidia is paying a premium for the memory stacks that accompany its GPUs, thereby channeling pricing power to memory suppliers like Micron.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Olawale Opayinka reveals how Eko Atlantic financial model was built

Founder and Managing Director of Makaya Consult FZE, Olawale Opayinka, has disclosed that he was brought in as far back as 2011 to develop...

  • Olawale Opayinka founded Makaya Consult FZE in 2011.
  • Actuarial scientist quantified uncertainty for Eko Atlantic model.
  • Nigeria's population growth could double Lagos in 15 years.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

  • Amgen is a global pharmaceutical giant with operations in 100+ countries
  • Axsome Therapeutics specializes in CNS disorders like depression and narcolepsy
  • Amgen's revenue heavily concentrated in 3 distributors, introducing risk

More from Saturday 29 August →